Clinical

Very elderly patients with acute myeloid leukemia have historically been limited to less intensive, less effective treatment regimens. A recent series of cases suggests age alone should not be a limiting factor for effective treatment.

Cholangiocarcinoma (CCA), or bile duct cancer, is classified by its location, with intrahepatic CCA (iCCA) referring to those cancers that form in bile ducts within the liver.

Drs Brinton and Slipczuk go into detail regarding an ideal multidisciplinary team for ASCVD treatment.

Drs Riddock and Slipczuk define “optimal care” for ASCVD from a system-level perspective with the use of quality metrics.

Trends in surveillance testing after treatment for colorectal cancer remained relatively stable recently, and patients who overutilized surveillance measures had quicker recurrence detection but higher costs.

A recent study sought to address what is known about proton pump inhibitors (PPIs) as a therapy for eosinophilic esophagitis and long-term outcomes in patients who respond to them as a way to guide treatment decisions.

A new study incorporated use of readings from continuous glucose monitors (CGMs) to establish reference sensor glucose ranges among healthy nondiabetic children aged 1 to 6 years.

In this study, investigators from Pennsylvania and New York evaluated outcomes among patients following their hospitalization for heart failure (HF) who did or did not participate in a remote monitoring program that included financial incentives for adherence.

Patients with acute myeloid leukemia (AML) who have undergone intensive chemotherapy are at a very high risk for invasive fungal disease, and a changing treatment landscape warrants further research on drug-drug interactions and outcomes.

To inform intervention development, we assessed for medication changes and patient care needs following treat-and-release Veterans Affairs emergency department visits for chronic ambulatory care–sensitive conditions.

The findings, say the researchers, provide a basis for future exploration of the activity of energy metabolism pathways in clonal plasma cells of patients newly diagnosed with the disease.

According to the researchers of this new study, the biomarker may have potential for use with clinical scores in treatment decisions or in clinical trials that focus on hidradenitis suppurativa (HS).

The researchers highlighted a need for the detection of more relevant markers and guidance on how to treat adverse events (AEs), the types and severity of which vary based on disease type.

In this study, outcomes were investigated among a cohort of patients with heart failure with reduced ejection fraction (HFrEF) who participated in a cardiac rehabilitation program post hospital discharge after they survived acute onset of HFrEF.

In this new study, researchers wrote of the implications that detailed an association between asthma and exposure to particulate matter less than or equal to 2.5 mcm.

New global data put the COVID-19 death toll at just under 15 million; the FDA issues a warning limiting use of Johnson & Johnson vaccine; US sees increase in aggressive uterine cancer cases.

Payer considerations regarding unintended pregnancy is discussed by Maria Lopes, MD, MS, and Kevin Stephens Sr., MD, JD.

Ayman Al-Hendy, MD, PhD identifies risk factors for development of US and endometriosis.

Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, addresses the placebo effect seen in clinical trials of chronic cough treatment.

This approval of trastuzumab deruxtecan (Enhertu) follows the March release of data from the DESTINY-Breast03 trial on the anti-HER2 monoclonal antibody, also a HER2-directed antibody-drug conjugate, which indicated superior outcomes vs trastuzumab emtansine.

Investigators found 6 genes associated with cancer-associated fibroblasts that appear to correlate with response to anti-PD-1 immunotherapy.

Drs Steven Levine, Patricia Ares-Romero, Samuel Nordberg, Martin Rosenzweig, and Carrie Jardine share insight on the future treatment landscape for TRD.

Dr Martin Rosenzweig discusses the importance of data collection to improve patient care in TRD as well as alternative payment models.

In patients with liver involvement, intrahepatic cholangiocarcinoma was a common diagnosis among some patients with cancer of unknown primary (CUP).

Limited evidence from a literature review suggests that co-pay assistance was associated with improved treatment persistence/adherence across various diseases, with indirect evidence suggesting improvements in clinical outcomes.